CSL Ltd
Company Profile
- Business description- CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. 
- Contact- 655 Elizabeth Street 
 MelbourneVIC3000
 AUS- T: +61 393891911 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Biotechnology - Fiscal Year End- 30 June 2026 - Employees- 29,904 
CSL Ltd News & Analysis
markets
Market Minute: Inflation figures hotter than expected
stocks
Are investors too bearish on Australian equities?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.90 | 5.00 | 0.05% | 
| CAC 40 | 8,147.35 | 53.53 | -0.65% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,721.06 | 35.08 | -0.36% | 
| HKSE | 26,282.69 | 63.45 | -0.24% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 51,325.61 | 17.96 | 0.04% | 
| NZX 50 Index | 13,489.89 | 30.60 | 0.23% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,885.50 | 5.50 | 0.06% | 
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |